The Indore maker wants a drug company to license the formula. It admits the combination has never been tested alongside a GLP-1 drug.
Recap by typeshit. Full story at Republic World.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Piramal plans to put $100 million into niche manufacturing this year while rivals pile into GLP-1, and says it won't go back to drug discovery.
Foundayo prescriptions rose from 57,920 the week before in its 27th week on sale. Oral Wegovy still leads on volume but fell from about 180K.
Loading…